The Symptom Check List SCL-90-Rand Its Ability to Discriminate between Dysthymia, Anxiety Disorders, and Anorexia nervosa

1992 ◽  
Vol 25 (3) ◽  
pp. 128-138 ◽  
Author(s):  
W. Rief ◽  
M. Fichter
Keyword(s):  
Anorexia Nervosa ◽  
Anxiety Disorders ◽  
Check List ◽  
Symptom Check List

Comparison of the Efficacy, Safety and Withdrawal of Alpidem and Alprazolam in Anxious Patients

1994 ◽  
Vol 165 (1) ◽  
pp. 94-100 ◽  
Author(s):  
Lodovico Frattola ◽  
Martine Garreau ◽  
Roberto Piolti ◽  
Sirio Bassi ◽  
Maria G. Albizzati ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Active Treatment ◽  
Withdrawal Syndrome ◽  
Withdrawal Symptoms ◽  
Check List ◽  
Double Blind ◽  
General Anxiety ◽  
Symptom Check List ◽  
Withdrawal Phase ◽  
Made In

BackgroundWe investigated whether a new non-benzodiazepine anti-anxiety drug, alpidem, produces weaker withdrawal symptoms than alprazolam.MethodUnder a double-blind procedure, 122 patients suffering from general anxiety disorders were randomly allocated to either alpidem (50 mg, three times a day) or alprazolam (0.5 mg, three times a day) for six weeks, followed by a two-week placebo withdrawal phase. The diagnosis of withdrawal syndrome (WS) was made, in blind conditions, on the basis of the Withdrawal Symptom Check List (WSCL), after one or two weeks of discontinuation of active treatment.ResultsThe WS occurred significantly less frequently in the alpidem group (n = 10, 18%) than in the alprazolam group (n = 26, 48%). Typical withdrawal symptoms on the WSCL were also significantly less severe (P = 0.044) in the alpidem group compared with the alprazolam group.ConclusionsAlpidem may be a valid alternative to current benzodiazepine anxiolytic therapy because it produces fewer and weaker withdrawal symptoms than alprazolam and is better tolerated.

Beeinträchtigtes Erkennen emotionaler Gesichtsausdrücke durch psychiatrische Patientinnen bei Alexithymie

2013 ◽  
Vol 61 (1) ◽  
pp. 7-15 ◽  
Author(s):  
Daniel Dittrich ◽  
Gregor Domes ◽  
Susi Loebel ◽  
Christoph Berger ◽  
Carsten Spitzer ◽  
...  
Keyword(s):  
Emotion Recognition ◽  
Emotional Expression ◽  
Depression Scale ◽  
Facial Emotion Recognition ◽  
Facial Emotion ◽  
Check List ◽  
Psychosomatische Erkrankungen ◽  
Psychiatrische Patienten ◽  
Symptom Check List ◽  
Tas 20

Die vorliegende Studie untersucht die Hypothese eines mit Alexithymie assoziierten Defizits beim Erkennen emotionaler Gesichtsaudrücke an einer klinischen Population. Darüber hinaus werden Hypothesen zur Bedeutung spezifischer Emotionsqualitäten sowie zu Gender-Unterschieden getestet. 68 ambulante und stationäre psychiatrische Patienten (44 Frauen und 24 Männer) wurden mit der Toronto-Alexithymie-Skala (TAS-20), der Montgomery-Åsberg Depression Scale (MADRS), der Symptom-Check-List (SCL-90-R) und der Emotional Expression Multimorph Task (EEMT) untersucht. Als Stimuli des Gesichtererkennungsparadigmas dienten Gesichtsausdrücke von Basisemotionen nach Ekman und Friesen, die zu Sequenzen mit sich graduell steigernder Ausdrucksstärke angeordnet waren. Mittels multipler Regressionsanalyse untersuchten wir die Assoziation von TAS-20 Punktzahl und facial emotion recognition (FER). Während sich für die Gesamtstichprobe und den männlichen Stichprobenteil kein signifikanter Zusammenhang zwischen TAS-20-Punktzahl und FER zeigte, sahen wir im weiblichen Stichprobenteil durch die TAS-20 Punktzahl eine signifikante Prädiktion der Gesamtfehlerzahl (β = .38, t = 2.055, p < 0.05) und den Fehlern im Erkennen der Emotionen Wut und Ekel (Wut: β = .40, t = 2.240, p < 0.05, Ekel: β = .41, t = 2.214, p < 0.05). Für wütende Gesichter betrug die Varianzaufklärung durch die TAS-20-Punktzahl 13.3 %, für angeekelte Gesichter 19.7 %. Kein Zusammenhang bestand zwischen der Zeit, nach der die Probanden die emotionalen Sequenzen stoppten, um ihre Bewertung abzugeben (Antwortlatenz) und Alexithymie. Die Ergebnisse der Arbeit unterstützen das Vorliegen eines mit Alexithymie assoziierten Defizits im Erkennen emotionaler Gesichtsausdrücke bei weiblchen Probanden in einer heterogenen, klinischen Stichprobe. Dieses Defizit könnte die Schwierigkeiten Hochalexithymer im Bereich sozialer Interaktionen zumindest teilweise begründen und so eine Prädisposition für psychische sowie psychosomatische Erkrankungen erklären.

scholarly journals Understanding the nature of association between anxiety phenotypes and anorexia nervosa: a triangulation approach

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
E. Caitlin Lloyd ◽  
Hannah M. Sallis ◽  
Bas Verplanken ◽  
Anne M. Haase ◽  
Marcus R. Munafò
Keyword(s):  
Anorexia Nervosa ◽  
Longitudinal Study ◽  
Anxiety Disorder ◽  
Anxiety Disorders ◽  
Causal Effect ◽  
Causal Effects ◽  
Observational Research ◽  
Genome Wide Association Studies ◽  
Genetic Liability ◽  
Depressed Affect

Abstract Background Evidence from observational studies suggests an association between anxiety disorders and anorexia nervosa (AN), but causal inference is complicated by the potential for confounding in these studies. We triangulate evidence across a longitudinal study and a Mendelian randomization (MR) study, to evaluate whether there is support for anxiety disorder phenotypes exerting a causal effect on AN risk. Methods Study One assessed longitudinal associations of childhood worry and anxiety disorders with lifetime AN in the Avon Longitudinal Study of Parents and Children cohort. Study Two used two-sample MR to evaluate: causal effects of worry, and genetic liability to anxiety disorders, on AN risk; causal effects of genetic liability to AN on anxiety outcomes; and the causal influence of worry on anxiety disorder development. The independence of effects of worry, relative to depressed affect, on AN and anxiety disorder outcomes, was explored using multivariable MR. Analyses were completed using summary statistics from recent genome-wide association studies. Results Study One did not support an association between worry and subsequent AN, but there was strong evidence for anxiety disorders predicting increased risk of AN. Study Two outcomes supported worry causally increasing AN risk, but did not support a causal effect of anxiety disorders on AN development, or of AN on anxiety disorders/worry. Findings also indicated that worry causally influences anxiety disorder development. Multivariable analysis estimates suggested the influence of worry on both AN and anxiety disorders was independent of depressed affect. Conclusions Overall our results provide mixed evidence regarding the causal role of anxiety exposures in AN aetiology. The inconsistency between outcomes of Studies One and Two may be explained by limitations surrounding worry assessment in Study One, confounding of the anxiety disorder and AN association in observational research, and low power in MR analyses probing causal effects of genetic liability to anxiety disorders. The evidence for worry acting as a causal risk factor for anxiety disorders and AN supports targeting worry for prevention of both outcomes. Further research should clarify how a tendency to worry translates into AN risk, and whether anxiety disorder pathology exerts any causal effect on AN.

Évolution sous traitement d’un groupe de 128 états dépressifs suivis en médecine générale

1986 ◽  
Vol 1 (2) ◽  
pp. 162-169
Author(s):  
D. Cremniter ◽  
J.D. Guelfi ◽  
J. Fermanian
Keyword(s):  
Effets Secondaires ◽  
Check List ◽  
Médecine Générale ◽  
Médecins Généralistes ◽  
Symptom Check List ◽  
La Modification

Résumé128 états dépressifs (24 hommes et 104 femmes) ont été inclus dans cette étude par 11 médecins généralistes sur une période de 4 mois. L’évaluation initiale (EO) montrait que 92 % des patients relevaient du diagnostic d’état dépressif selon la liste des critères de Spitzer (RDC, 1977) dont 72 % de dépressions majeures et 20 % de dépressions mineures. La note obtenue à la MADRS (échelle de dépression de Montgomery et Asberg) à EO était supérieure à 20 chez les 3/4 des patients. La fréquence des traitements prescrits se répartissait ainsi : anxiolytiques (74.2 % des patients), antidépresseurs (68 %) et somnifères (22.6 %). Après 15 jours d’évolution sous traitement, 99 patients ont été revus lors de la 2ème évaluation (E1). La diminution des scores obtenus à la MADRS se situe entre 0 et 50% chez 54 patients et atteint plus de 50 % chez 32 patients. Le jugement global du généraliste confirme l’importance du taux d’amélioration portant sur 80 % des patients. Parmi ceux-ci, un degré marqué d’amélioration est retrouvé chez 45 % des déprimés traités par antidépresseurs alors qu’il n’est que de 22 % de ceux qui ne reçoivent pas ce traitement. Les effets secondaires sont présents chez 45 % des patients à E1. Chez ceux traités par les antidépresseurs, la fréquence de survenue de ces effets est nettement plus importante (43 %) que chez ceux qui ne reçoivent pas ce traitement (15 %).Au cours de l’évolution, la modification des scores de la HSCL (Hopkins Symptom Check-List) est mesurée chez 43 des patients revus lors de la 3ème évaluation (E2) un mois après le début du traitement. Les 7 dépressions majeures sont toutes améliorées. Sur les 30 dépressions majeures, la diminution des scores porte sur les 5/6 des patients.

scholarly journals Adapting a neuroscience-informed intervention to alter reward mechanisms of anorexia nervosa: a novel direction for future research

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Ann F. Haynos ◽  
Lisa M. Anderson ◽  
Autumn J. Askew ◽  
Michelle G. Craske ◽  
Carol B. Peterson
Keyword(s):  
Anorexia Nervosa ◽  
Eating Disorder ◽  
Anxiety Disorders ◽  
Reward Processing ◽  
Future Research ◽  
Restrictive Eating ◽  
Eating Disorder Symptoms ◽  
Mood And Anxiety Disorders ◽  
Reward Responsivity ◽  
Eating Disorder Behaviors

AbstractAccumulating psychobiological data implicate reward disturbances in the persistence of anorexia nervosa (AN). Evidence suggests that individuals with AN demonstrate decision-making deficits similar to those with mood and anxiety disorders that cause them to under-respond to many conventionally rewarding experiences (e.g., eating, interacting socially). In contrast, unlike individuals with other psychiatric disorders, individuals with AN simultaneously over-respond to rewards associated with eating-disorder behaviors (e.g., restrictive eating, exercising). This pattern of reward processing likely perpetuates eating-disorder symptoms, as the rewards derived from eating-disorder behaviors provide temporary relief from the anhedonia associated with limited responsivity to other rewards. Positive Affect Treatment (PAT) is a cognitive-behavioral intervention designed to target reward deficits that contribute to anhedonia in mood and anxiety disorders, including problems with reward anticipation, experiencing, and learning. PAT has been found to promote reward responsivity and clinical improvement in mood and anxiety disorders. This manuscript will: (1) present empirical evidence supporting the promise of PAT as an intervention for AN; (2) highlight nuances in the maintaining processes of AN that necessitate adaptations of PAT for this population; and (3) suggest future directions in research on PAT and other reward-based treatments that aim to enhance clinical outcomes for AN.

Variations in responses to a symptom check-list by age, sex, income, residence and ethnicity

1972 ◽  
Vol 7 (3) ◽  
pp. 150-156 ◽  
Author(s):  
F. Engelsmann ◽  
H. B. M. Murphy ◽  
R. Prince ◽  
M. Leduc ◽  
H. Demers
Keyword(s):  
Check List ◽  
Symptom Check List

scholarly journals Psychopathology and urine toxicology in methadone patients

2015 ◽  
Vol 7 (1) ◽  
Author(s):  
Gamal Sadek ◽  
Zack Cernovsky ◽  
Simon Chiu
Keyword(s):  
Psychotic Symptoms ◽  
Social Self ◽  
Check List ◽  
Obsessive Compulsive ◽  
Paranoid Ideation ◽  
Compulsive Disorder ◽  
Self Confidence ◽  
Urine Toxicology ◽  
Symptom Check List ◽  
Methadone Patients

Several studies reported high rates of psychiatric commorbidity among methadone patients. We examined the relationships of measures of psychopathology to outcomes of screening urine tests for cocaine, opiates, and benzodiazepines in a sample of 56 methadone patients. They also completed the Symptom Check List-90-Revised (SCL-90-R). The highest scales in the SCL-90-R profile of our patients were those indicating somatic discomfort, anger, phobic anxiety, paranoid ideation, and also obsessive-compulsive disorder symptoms (scores above the 39th percentile). The only significant correlations between urine tests and SCL-90-R psychopathology were those involving benzodiazepines: patients with urine tests positive for benzodiazepines had lower social self-confidence (r=0.48), were more obsessive-compulsive (r=0.44), reported a higher level of anger (r=0.41), of phobic tendencies (r=40), of anxiety (r=0.39), and of paranoid tendencies (r=0.38), and also reported more frequent psychotic symptoms (r=0.43).

Differences in the symptom check list‐90 profiles of black and white methadone patients

1989 ◽  
Vol 45 (2) ◽  
pp. 342-345
Author(s):  
Jerome J. Platt ◽  
Robert A. Steer ◽  
William F. Ranieri ◽  
David S. Metzger
Keyword(s):  
Check List ◽  
Black And White ◽  
Symptom Check List ◽  
Methadone Patients
Sign in / Sign up

Export Citation Format

Share Document